United States Narcolepsy Therapeutics Market Landscape Transformed by Drug Pipelines and Research

global narcolepsy therapeutics market reached US$ 2.93 billion in 2023, with a rise to US$ 3.19 billion in 2024, and is expected to reach US$ 6.98 billion by 2033, growing at a CAGR of 9.1% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/narcolepsy-therapeutics-market?kb

United States: Recent Industry Developments

🔹 Nov 2025: Jazz Pharmaceuticals advanced Phase III trials for next-generation oxybate therapy designed for twice-monthly dosing to improve treatment adherence.

🔹 Oct 2025: Harmony Biosciences expanded the availability of pitolisant therapy for pediatric narcolepsy patients across specialty sleep centers.

🔹 Sep 2025: New digital therapeutics tools integrating sleep-tracking and AI-based symptom diaries became available for narcolepsy management.

GCC: Recent Industry Developments

🔹 Nov 2025: UAE healthcare authorities introduced fast-track regulatory approvals for breakthrough narcolepsy drugs to support neurological care.

🔹 Oct 2025: Saudi Arabia launched multidisciplinary sleep clinics focusing on behavioral therapy in combination with pharmacological treatments.

🔹 Sep 2025: Qatar expanded access to orexin-targeting therapies under national insurance coverage programs.

MENA: Recent Industry Developments

🔹 Nov 2025: Egypt initiated clinical research collaborations to evaluate the effectiveness of sodium oxybate therapy across different age groups.

🔹 Oct 2025: Morocco increased imports of novel wakefulness-promoting agents for treatment-resistant narcolepsy cases.

🔹 Sep 2025: Regional hospitals adopted tele-sleep platforms to improve patient follow-up and medication adherence for narcolepsy patients.

Major Growing Players:

Jazz Pharmaceuticals, Inc., Avadel, Apotex Inc., Novartis AG, and Harmony Biosciences

Key Developments:

1. In January 2025, Apotex Inc. reported that its affiliate, Nuvo Pharmaceuticals (Ireland) DAC, acquired the U.S. rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil). This acquisition expands the Apotex Group's global portfolio, which now includes more than 550 generic, branded, OTC, and biosimilar products.

2. In June 2024, Harmony Biosciences received FDA approval for its supplemental NDA for WAKIX® (pitolisant) tablets to treat excessive daytime sleepiness (EDS) in pediatric patients aged 6 years and older diagnosed with narcolepsy. The FDA issued two separate decisions-granting approval for the EDS indication while issuing a complete response regarding cataplexy treatment for this age group.

Forecast Projection:

The Global Narcolepsy Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Latest M&A

1. Alkermes buys Avadel ($2.1B, 2025): Enters sleep market via Lumryz (94% patient preference vs. twice-nightly oxybate); $1B upfront + $1.1B milestones; launches Q4 2025.​

2. Apotex acquires US rights to Provigil/Nuvigil (Feb 2025): From Neuraxpharm; bolsters stimulants portfolio.​

3. Harmony Biosciences HBS-102 acquisition (double-digit millions, 2025): MCHR1 antagonist for REM dysregulation

Research Process:

Global Narcolepsy Therapeutics Market report is built on solid intelligence - powered by both primary and secondary research. Our analysts have deep-dived into every factor that can influence your business roadmap, including government regulations, competitive landscape, tech innovations, historical market behavior, upcoming breakthroughs, adjacent industry trends, market volatility, growth prospects, and potential risks.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports): https://www.datamintelligence.com/buy-now-page?report=narcolepsy-therapeutics-market?kb

Key Segments:

By Disease Type: (Narcolepsy Type 1, Narcolepsy Type 2)

By Therapeutic Type: (Central Nervous System Stimulants, Central Nervous System Depressants, Others)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Other Pharmacies)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: sets the stage by defining the full scope of the report and delivering an executive summary of key market segments across regions, product types, and applications. It provides a comprehensive snapshot of current market sizes and reveals future growth potential, offering a clear vision of how the market will evolve in the short, mid, and long term.

Chapter 2: uncovers critical insights and highlights the most impactful emerging trends shaping the Narcolepsy Therapeutics market's future - essential knowledge for investors and strategists looking to stay ahead.

Chapter 3: dives deep into the competitive landscape, delivering an in-depth analysis of Narcolepsy Therapeutics manufacturers. It covers market share dynamics, strategic developments, and the latest mergers and acquisitions that are redefining the industry.

Chapter 4: profiles the market's leading players, offering detailed views of their revenue streams, profit margins, product portfolios, and recent innovations - arming you with the intel to benchmark and strategize effectively.

Chapters 5 & 6: break down revenue performance by region and country, providing a quantitative analysis that spotlights growth hotspots, development prospects, and the unique opportunities each market offers across the globe.

Chapter 7: explores market segmentation by type, revealing the size and untapped potential of each segment - guiding you toward lucrative "blue ocean" opportunities that competitors may have overlooked.

Chapter 8: analyzes the market by application, evaluating downstream sectors with the highest growth potential and identifying promising areas for expansion and investment.

Chapter 9: maps the entire industry supply chain, tracing upstream suppliers to downstream distributors, giving you full visibility into critical business linkages and value drivers.

Chapter 10: wraps up with a powerful summary of the report's key findings and strategic takeaways, delivering the must-know insights every industry stakeholder needs to make confident, forward-looking decisions.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/narcolepsy-therapeutics-market?kb

Government Regulations & FDA/EMA Approvals

FDA:

1. Suzetrigine (Journavx): Non-opioid NaV1.8 blocker approved Jan 2025 for acute pain (CLBP/narcolepsy-relevant).​

2. EMA: Wakix (pitolisant) pediatric extension (Sep 2025): Ages 6+ for EDS/cataplexy.​
China NMPA: RareStone pitolisant (Wakix) approved Aug 2025: First non-scheduled narcolepsy drug.​

3. Guidelines: Orphan designations (XWL-008); FDA non-opioid chronic pain draft (Sep 2025).

Have Detailed Enquiry of This Report @ https://www.datamintelligence.com/enquiry/narcolepsy-therapeutics-market?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.